Evaluating the Impact of Cell Therapy on Patient Safety to Enhance Long-Term Outcomes in B-Cell-Targeted Autoimmune Therapies
Time: 12:15 pm
day: Conference Day Two Teal Track
Details:
- Evaluate clinical safety and monitoring side effects associated with CAR-T therapies
- Investigate prevention of cytokine released syndrome (CRS) and (ICANS) associated with CAR-T and T-cell engagers
- Introducing a small molecule oral immune modulator called CTO-1,681, to effectively enhance safety outcomes and expand patient access
